TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34817600

Group type: EXPERIMENTAL
Intervention: Group A (24 experts)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group B (28 experts)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Full-group analysis
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Parallel-group analysis
Number of subjects: 52
Study: 33287865

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT) for 12 months
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard probation as usual (Control)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 302
Study: 33406997

Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA) at 0° deviation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA) at 15° deviation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA) at 30° deviation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (wedge prisms)
Number of subjects: 15
Study: 33789243

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5 mg·kg‐1 body mass
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 12
Study: 32781992

Group type: EXPERIMENTAL
Intervention: Oral ranitidine (3 mg/kg/day) for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotic (5 to 10 billion CFUs of Lactobacillus rhamnosus) for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (50 mg of oral vitamin C tablet) for 10 days
Number of subjects: 40
Study: 36210273

Group type: EXPERIMENTAL
Intervention: Time-lapse incubator
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Standard incubator
Number of subjects: 1224
Study: 33839918

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (AMP)
Number of subjects: 459

Group type: COMPARATOR
Intervention: No antimicrobial prophylaxis (no AMP)
Number of subjects: 459
Study: 32170786

Group type: EXPERIMENTAL
Intervention: Premature birth
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Behavioural states (quiet and awake)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Behavioural states (active and asleep)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Behavioural states (quiet and asleep)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Duration of the heel stick procedure
Number of subjects: 154
Study: 35859277

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP ≤ 130 mmHg)
Number of subjects: 3176

Group type: COMPARATOR
Intervention: Standard treatment (SBP ≤ 140 mmHg)
Number of subjects: 3176
Study: 34646359

Group type: EXPERIMENTAL
Intervention: Aloe extract (n = 38)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control treatment (n = 33)
Number of subjects: 213
Study: 32964514

Group type: EXPERIMENTAL
Intervention: Study treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: External control group
Number of subjects: 0
Study: 34042953

Group type: EXPERIMENTAL
Intervention: Biological VNN (BioVNN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional neural networks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neural network based on randomized pathways
Number of subjects: 0
Study: 32883104

Group type: EXPERIMENTAL
Intervention: ON-hours admission
Number of subjects: 686

Group type: COMPARATOR
Intervention: OFF-hours admission
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 686

Group type: COMPARATOR
Intervention: Immediate multivessel PCI
Number of subjects: 686
Study: 33724391

Group type: EXPERIMENTAL
Intervention: Standard bupivacaine
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 280

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 280
Study: 32801102

Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL) 1200 mg once daily (QD)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL) 800 mg once daily (QD)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL)
Number of subjects: 547
Study: 33864234

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Continued Behavioral Weight-Loss Treatment (Control)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Baseline Weight-Related Experiential Avoidance (AAQW-R)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Post-Treatment Weight-Related Experiential Avoidance (AAQW-R)
Number of subjects: 68
Study: 33742664

Group type: EXPERIMENTAL
Intervention: Precommitment intervention (upfront voluntary choice restriction)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no precommitment)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Precommitment intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Add-on self-directed cognitive training
Number of subjects: 83
Study: 32799787

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic donor nephrectomy
Number of subjects: 75
Study: 34878953

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440 mg (NapS)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Hydrocodone plus acetaminophen 10/650 mg (HYD+APAP)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 32798172

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Pecto-intercostal fascial block with 0.25% bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 36058564

Group type: EXPERIMENTAL
Intervention: Methylprednisolone taper (MPT) course following surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (preoperative dexamethasone only)
Number of subjects: 56
Study: 32829027

Group type: EXPERIMENTAL
Intervention: CLS-TA plus intravitreal aflibercept (active group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Aflibercept monotherapy (control group)
Number of subjects: 71
Study: 32915843

Group type: EXPERIMENTAL
Intervention: Derivation cohort (n = 1,273)
Number of subjects: 4139

Group type: EXPERIMENTAL
Intervention: Validation cohort (n = 636)
Number of subjects: 4139

Group type: EXPERIMENTAL
Intervention: Japan-CTO extension score
Number of subjects: 4139
Study: 35798710

Group type: EXPERIMENTAL
Intervention: Compacted dual-head power toothbrush (DH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single-head power toothbrush (SH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Compacted dual-head power toothbrush (DH) for 45 seconds
Number of subjects: 24
Study: 34135055

Group type: EXPERIMENTAL
Intervention: Vitamin A and Vitamin D supplementation
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 32718550

Group type: EXPERIMENTAL
Intervention: Risk prediction model for thromboembolic events
Number of subjects: 72381

Group type: EXPERIMENTAL
Intervention: Risk prediction model for MACE
Number of subjects: 72381

Group type: COMPARATOR
Intervention: CHADS2 risk model
Number of subjects: 72381

Group type: COMPARATOR
Intervention: CHA2DS2-VASc risk model
Number of subjects: 72381
Study: 35166687

Group type: EXPERIMENTAL
Intervention: BetterLife smartphone app for 10 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group on waiting list for 10 weeks
Number of subjects: 126
Study: 34852781

Group type: EXPERIMENTAL
Intervention: TIVA (propofol and remifentanil)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SEVO (sevoflurane and remifentanil)
Number of subjects: 80
Study: 32314841

Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing and standard ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: No pacing and HFJV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing and HFJV
Number of subjects: 40

Group type: COMPARATOR
Intervention: No pacing and standard ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pacing and HFJV together
Number of subjects: 40
Study: 35346048

Group type: EXPERIMENTAL
Intervention: Intraoperative dopamine infusion
Number of subjects: 294

Group type: COMPARATOR
Intervention: Intraoperative norepinephrine use
Number of subjects: 294
Study: 32643361

Group type: EXPERIMENTAL
Intervention: Hemoadsorption (CytoSorb®)
Number of subjects: 15
Study: 32436160

Group type: EXPERIMENTAL
Intervention: Magnesium citrate lozenges
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Magnesium citrate tablets
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (tablets or lozenges)
Number of subjects: 80
Study: 36471322

Group type: COMPARATOR
Intervention: High Degree of Implementation (DOI)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Low Degree of Implementation (DOI)
Number of subjects: 476
Study: 33839618

Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone
Number of subjects: 307
Study: 35887695

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) 1000 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) 2000 mg
Number of subjects: 54
Study: 32970554

Group type: EXPERIMENTAL
Intervention: COVID‐19 self‐triage website
Number of subjects: 877
Study: 35561333

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stoves
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Improved chimney stove
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Traditional solid fuel (TSF) stoves with built-in chimney
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Kitchen chimneys
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Control group (traditional solid fuel without improved technology)
Number of subjects: 1205
Study: 33526618

Group type: EXPERIMENTAL
Intervention: Filgotinib + MTX
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Filgotinib monotherapy
Number of subjects: 739
Study: 32139286

Group type: EXPERIMENTAL
Intervention: Tension band wiring (TBW)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plate fixation (PF) with locking screws
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of TBW and PF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Construct stiffness measurement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclic test
Number of subjects: 20

Group type: COMPARATOR
Intervention: Load-to-failure test
Number of subjects: 20
Study: 34338105

Group type: EXPERIMENTAL
Intervention: The Pause (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33089364

Group type: EXPERIMENTAL
Intervention: Hypercapnia (5% inspired CO2, +7 mmHg PETCO2) during LBNP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normocapnia (room air) during LBNP
Number of subjects: 12
Study: 32867959

Group type: EXPERIMENTAL
Intervention: QCT-generated bone mineral content (BMC) analysis
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: QCT BMC vs actual ash weight comparison
Number of subjects: 125
Study: 36209129

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Spikevax®)
Number of subjects: 600

Group type: COMPARATOR
Intervention: BNT162b2 (Comirnaty®)
Number of subjects: 600
Study: 34064438

Group type: EXPERIMENTAL
Intervention: Interoception group (n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 61
Study: 34551895

Group type: EXPERIMENTAL
Intervention: Nurse led follow-up via telehealth including serum CA125 monitoring and completion of the MOST-S26
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine clinic based follow-up
Number of subjects: 150
Study: 32209529

Group type: EXPERIMENTAL
Intervention: iHOPE programme
Number of subjects: 114
Study: 34124817

Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to MAA‐LDL
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to heat shock protein 60 of Aggregatibacter actinomycetemcomitans
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to Porphyromonas gingivalis
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to A. actinomycetemcomitans
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to P. intermedia
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Total IgA
Number of subjects: 423
Study: 32915512

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 33638577

Group type: EXPERIMENTAL
Intervention: Radiomics signature comprising five handcrafted and one deep learning-based features
Number of subjects: 97
Study: 32529343

Group type: EXPERIMENTAL
Intervention: Usual care with QoL-monitor
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 113
Study: 36256912

Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg once daily plus olaparib 200 mg twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Olaparib 300 mg twice daily alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg once daily plus olaparib 200 mg twice daily in HRR-deficient mCRPC
Number of subjects: 90

Group type: COMPARATOR
Intervention: Olaparib 300 mg twice daily alone in HRR-deficient mCRPC
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg once daily plus olaparib 200 mg twice daily in BRCA2-mutated mCRPC
Number of subjects: 90

Group type: COMPARATOR
Intervention: Olaparib 300 mg twice daily alone in BRCA2-mutated mCRPC
Number of subjects: 90
Study: 33466699

Group type: EXPERIMENTAL
Intervention: Motor Imagery Training Group (MITG)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Task‐Oriented Training Group (TOTG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 34
Study: 36181009

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No colchicine (Control)
Number of subjects: 0
Study: 33177220

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block type 3 (QLB3)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lumbar plexus block (LPB)
Number of subjects: 46
Study: 32003735

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nasal resistance measurement
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mandibular advancement
Number of subjects: 39
Study: 35148689

Group type: EXPERIMENTAL
Intervention: tPRK
Number of subjects: 72

Group type: COMPARATOR
Intervention: mPRK
Number of subjects: 72

Group type: COMPARATOR
Intervention: aaPRK
Number of subjects: 72

Group type: COMPARATOR
Intervention: mPRK and aaPRK
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: tPRK, mPRK, aaPRK
Number of subjects: 72
Study: 33001491

Group type: EXPERIMENTAL
Intervention: TMFI + ALA-cream
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TMFI + ALA-gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: ALA-cream
Number of subjects: 12
Study: 34672356

Group type: EXPERIMENTAL
Intervention: Behavioural medical rehabilitation
Number of subjects: 720

Group type: COMPARATOR
Intervention: Common rehabilitation programme
Number of subjects: 720
Study: 32674202

Group type: EXPERIMENTAL
Intervention: Diabetes Group Prenatal Care
Number of subjects: 84

Group type: COMPARATOR
Intervention: Individual Prenatal Care
Number of subjects: 84
Study: 33676327

Group type: EXPERIMENTAL
Intervention: Nomogram using clinical features and biochemical parameters to predict DVT risk
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Nomogram with independent risk factors (older age ≥65 years, female gender, hemorrhagic stroke, malignancy, lower limb muscle strength <3 grade, Albumin <40 g·L−1, D‐dimer >0.5 mg·L−1)
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1651
Study: 32532700

Group type: EXPERIMENTAL
Intervention: Food deprivation of 8 hours
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Food deprivation of 4 hours
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading directly prior to the laparoscopic exam
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Self-reported level of appetite (intermediate level)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Self-reported level of appetite (hungry)
Number of subjects: 37
Study: 34713770

Group type: EXPERIMENTAL
Intervention: Progressive neuromuscular exercise program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Progressive neuromuscular exercise program + corrective kinesio taping
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (exercise only)
Number of subjects: 30
Study: 34886430

Group type: EXPERIMENTAL
Intervention: Physical Activity Behavior Change Counseling (PABCC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard exercise program (control)
Number of subjects: 93
Study: 32710482

Group type: EXPERIMENTAL
Intervention: nsCL/P polygenic risk scores (PRS)
Number of subjects: 10448
Study: 35042489

Group type: EXPERIMENTAL
Intervention: Kedo‐S‐Square rotary file
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hand stainless steel K file
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hand stainless steel H file
Number of subjects: 60
Study: 33843663

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OT) group, 20-25 μg/ml ozone concentration, 30 ml, 8 sessions total
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo control (PC) group, 0.1 μg/ml ozone concentration, 30 ml, 8 sessions total
Number of subjects: 38
Study: 36455170

Group type: EXPERIMENTAL
Intervention: Mixed simulation (360° virtual reality and high-fidelity simulator)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (traditional simulation)
Number of subjects: 49
Study: 32026271

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (AVD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled sedation (PCS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Historical clinician-controlled propofol usage
Number of subjects: 50
Study: 32333564

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training + virtual reality
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard robot-assisted gait training
Number of subjects: 17
Study: 34952141

Group type: EXPERIMENTAL
Intervention: Multiple schedule (φ = 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed signals (φ = 0.8, 0.4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed schedule (φ = 0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32127336

Group type: EXPERIMENTAL
Intervention: Low-dose prasugrel (5 mg)
Number of subjects: 1408

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1408
Study: 36696208

Group type: EXPERIMENTAL
Intervention: Young women cluster
Number of subjects: 3062

Group type: EXPERIMENTAL
Intervention: Young men cluster
Number of subjects: 3062

Group type: EXPERIMENTAL
Intervention: Older people cluster
Number of subjects: 3062

Group type: COMPARATOR
Intervention: Comorbidity cluster
Number of subjects: 3062
Study: 32282356

Group type: EXPERIMENTAL
Intervention: Intraoperative riboflavin 0.10% every minute
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intraoperative riboflavin 0.10% every 2 minutes
Number of subjects: 43
Study: 33579222

Group type: EXPERIMENTAL
Intervention: Health education sessions on obstetric danger signs and birth preparedness
Number of subjects: 300
Study: 32422966

Group type: EXPERIMENTAL
Intervention: FeNO measurement over 28 parts per billion (pbb)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clinical evaluation of rhinitis symptoms, total immunoglobulin E (IgE), ICAM‐1, VCAM‐1, E‐selectin, and IL‐6 levels
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Age over 30 years
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Duration of allergic rhinitis over 12 months
Number of subjects: 58
Study: 35776501

Group type: EXPERIMENTAL
Intervention: GAD-alum (4 μg) administered intralymphatically three times with 1 month interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34151951

Group type: EXPERIMENTAL
Intervention: Genetically predicted lipid and apolipoprotein levels (including LDL-C, triglycerides, apolipoprotein B, HDL-C)
Number of subjects: 331368

Group type: EXPERIMENTAL
Intervention: Higher UACR
Number of subjects: 331368

Group type: COMPARATOR
Intervention: Reverse causal effect of eGFR
Number of subjects: 331368
Study: 35869467

Group type: EXPERIMENTAL
Intervention: Comprehensive Corrective Exercise Program (CCEP) performed for three sessions per week for eight weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Activities of daily living (Control group)
Number of subjects: 30
Study: 33568380

Group type: EXPERIMENTAL
Intervention: Telephone-based collaborative care intervention delivered by experienced public health nurses including detailed risk assessments, individualised structured management plans, scheduled follow-up calls, and access to a web-based app with individualised, evidence-based resources.
Number of subjects: 5229

Group type: EXPERIMENTAL
Intervention: Telephone-based collaborative care intervention
Number of subjects: 5229
Study: 32856619

Group type: EXPERIMENTAL
Intervention: 200 mL of a carbohydrate beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure water (control group)
Number of subjects: 0
Study: 36349660

Group type: EXPERIMENTAL
Intervention: Energy-balanced diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Energy-restricted diet (43 ± 3% energy deficit)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ambulatory vigilance assessment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mood assessment
Number of subjects: 10
Study: 33456047

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuvers (RM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 42
Study: 32446951

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone before radiation therapy followed by 3 daily doses (group A)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone followed by 3 doses of placebo (group B)
Number of subjects: 295

Group type: COMPARATOR
Intervention: 4 doses of placebo (group C)
Number of subjects: 295